Transdermal fentanyl as an adjuvant to paravertebral block for pain control after breast cancer surgery: A randomized, double-blind controlled trial

ABSTRACT

Objective: The aim of this study is to investigate the effect of transdermal fentanyl (TDF) as an adjuvant to paravertebral block (PVB) for pain control after breast cancer surgery.

Patients and Methods: This randomized, double-blind trial included fifty females with breast cancer scheduled for surgery. They were randomly allocated into one of two equal groups. The TDF group used transdermal fentanyl patches (TFPs) 25 μg/h applied 10 h preoperative then PVB with 20 mL of bupivacaine 0.25% was done before induction of general anesthesia. The PVB group used placebo patches in addition to PVB the same way as TDF group. Postoperative pain was assessed with a visual analog scale (VAS) score up to 48 h. Intravenous morphine 0.1 mg/kg was given when the VAS is ≥ 3 or on patient request. The primary outcome measures were the time to first request for analgesia and the total analgesic consumption in the first 48 h.

Results: Relative to the VAS score reading was 30 min. After the end of surgery, VAS score decreased significantly in the two groups up to 48 postoperative hours and was significantly lower in TDF group up to 24 h. The time to first request of additional analgesia was significantly longer, and total dose of morphine consumption was significantly lower in TDF group (P < 0.001, and P = 0.039, respectively).

Conclusion: TFPs releasing 25 μg/h is a safe and effective adjuvant to PVB after breast cancer surgery. It provides adequate analgesia with reduction of opioid consumption and minimal adverse effects.

Key words: Breast cancer; fentanyl patches; postoperative pain

Introduction

Breast cancer is by far the world's most common cancer among women.[1] In Egypt, breast cancer represents 32% of all cancers among females.[2] Postoperative pain is a main concern for patients following any type of surgery. Despite the increased awareness of pain management, postoperative pain is reported by about 80% of surgical patients.[3] Insufficient pain control may impair pulmonary functions and increase the risk of ileus and thromboembolism.[4] Nevertheless, pain medications are associated with adverse effects in nearly 25% of patients.[3] On the other hand, regional anesthesia is an attractive alternative that can offer adequate analgesia with reduction of opioid consumption and its side effects.[5]
For patients undergoing mastectomy, thoracic paravertebral block (PVB) is currently the “gold standard” regional anesthetic technique. PVB provides anesthesia or analgesia to the chest wall and has been associated with decreased opioid consumption.\[6,7\]

The transdermal fentanyl patch (TFP) is a skin-patch opioid that steadily releases dose-dependent fentanyl into the bloodstream.\[8\] It provides a plasma level similar to intravenous (IV) use.\[9\] TFP has a slow onset and thus is commonly used for chronic pain management.\[10,11\]

As a preemptive analgesia, if TFP is applied before surgery, it can be used to relieve postoperative pain. The concept of multimodal analgesia is intended to maximize efficacy and minimize side effects of more than one analgesic technique. This was the basis of the current study which aims to investigate the effect of transdermal fentanyl (TDF) as an adjuvant to PVB for pain control after breast cancer surgery.

**Patients and Methods**

This study was carried out in the National Cancer Institute during the period from April to August 2016. It included 50 adult females with breast cancer with physical status American Society of Anesthesiologists (ASA) Class II or III scheduled for surgery. A written informed consent was obtained from each participant after full explanation of the purpose and procedure of the study. Privacy of participants and confidentiality of data were ensured according to the Declaration of Helsinki. The study was approved by the institutional and the regional ethical committee of Cairo University National Cancer Institutional Review Board, 22/03/2016, ref: 201516015.2 ISRCTN76105318.

Patients with central neuropathy, bleeding disorders (coagulopathy), psychiatric illnesses, history of drug abuse and chronic analgesic use, history of allergy to study drugs, infection at the injection site, and liver or renal impairment were excluded from the study.

Using sealed envelopes, participants were randomly classified into two equal groups, each of 25 patients. Patients of TDF group used TFPs 25 μg/h (Durogesic®, Janssen Pharmaceutics, Belgium) 10 h before induction of anesthesia. Then, PVB was performed using 20 mL of bupivacaine 0.25% before induction of general anesthesia. Patients of the PVB group used placebo patches 10 h before induction of anesthesia received only PVB before induction of general anesthesia the same way as TDF group. Patches were applied by an independent nurse blinded of the study protocol.

**Assessment and monitoring**

Medical and surgical histories of the patient were evaluated, clinical examination and routine laboratory investigations were done including complete blood picture, prothrombin time and activity, liver, and renal functions. Routine monitoring of heart rate and rhythm by Electrocardiography, arterial blood pressure using noninvasive blood pressure including systolic, diastolic, and mean arterial blood pressure, peripheral oxygen saturation (SPO2) using pulse oximetry were secured. An IV line was established with an 18-gauge cannula and lactated Ringer’s solution 10 mL/kg was infused over 10 min before the initiation of anesthesia. All patients received incremental IV doses of midazolam (1–3 mg) and fentanyl (50–100 μg) for sedation.

**Technique of paravertebral block**\[12\]

Intradermal lidocaine is used at the site of the needle insertion. The superior aspects of the spinous processes T1–T6 are marked. The skin entry points are 3 cm lateral to the marks. A 22-gauge needle is inserted perpendicularly to the skin for a distance of 2–4 cm until the transverse process is contacted. The needle is withdrawn and walked cephalad off the transverse process and advanced for a further 1.5–2 cm. Bupivacaine 0.25% is administered paravertebrally in a dose of 20 mL divided into 3–4 mL in each level. The time for performance of the block ranges from 10 to 15 min. The success of the block is tested by decreased pinprick sensation at the expected dermatomal level (T1–T6). Immediately after the block, the patient is placed in the supine position.

**Anesthetic technique**

General anesthesia was induced by fentanyl (1.5 μg/kg), propofol (2–3 mg/kg), and lidocaine (1.5 mg/kg). Endotracheal intubation was facilitated by cisatracurium (0.15 mg/kg). Anesthesia was maintained by isoflurane 1–1.5 Minimum alveolar concentration. Fentanyl 0.5 μg/kg and cisatracurium 0.03 mg/kg were given when indicated. Patients were mechanically ventilated to maintain ETCO2 between 33 and 36 mmHg.

Heart rate and blood pressures were recorded preoperatively and after 30 min, 60 min, and 120 min. Hypotension is defined as a 15% decrease in systolic blood pressure from the baseline. Bradycardia is defined as a heart rate < 50 beats/min or as an inappropriately slow heart rate despite hypotension. Hypoxia is defined as an SPO2 < 90%. Hypotension was treated with IV boluses of ephedrine 0.1 mg/kg and normal saline 5 mL/kg and repeated as required. Bradycardia was treated with IV atropine 0.01 mg/kg.

**Postoperative care**

In the postanesthesia care unit vital signs (heart rate, blood pressure, respiratory rate, and SPO2) were monitored. The
level of sedation using a modified Observer’s Assessment of Alertness/Sedation (OAA/S) Scale\(^\text{[13]}\) was recorded; where 1 = awake/alert to 5 = sleep/unarousable. The pain was assessed at rest and with movement by visual analog scale (VAS) score, immediately and 2, 4, 6, 12, 24, 36, and 48 h postoperatively. All patients received 1 g IV paracetamol every 8 h, and IV morphine 0.1 mg/kg was given when the VAS is ≥3 or on patient request.

The primary outcome measures were the time to first request for analgesia and the total analgesic consumption in the first 48 h. The secondary outcome measures were postoperative adverse effects, namely, nausea, vomiting, hypotension, bradycardia, and cardiac arrhythmia, and postoperative complications of the block including accidental pneumothorax and vascular puncture.

Sample size calculation

The sample size was calculated using the G*Power\(^\circledR\) software (Institut für Experimentelle Psychologie, Heinrich-Heine-Universität, Düsseldorf, Germany) version 3.1.9.2. In a previous study\(^\text{[14]}\) using TFP reduced morphine consumption during the first 24 postoperative hours to 15.4 ± 12.7 mg compared 33.6 ± 19.1 mg in the placebo-controlled group. Based on the results of this study, a sample of 18 patients in each group is required to elicit the difference at an alpha level of 0.05 and a power of the study of 90%.

Statistical analysis

Statistical analysis of the data was performed using IBM\(^\circledR\) SPSS\(^\circledR\) Statistics version 22 (IBM\(^\circledR\) Corp., Armonk, NY, USA). Numerical variables were presented as a mean and standard deviation or median and range as appropriate. The intergroup differences were compared using the independent samples Student’s t-test or Mann–Whitney test for numerical variables. Chi-square test (Fisher’s exact test) was used to examine the relation between qualitative variables. Two-way analysis of variance was used to test the interaction between the two groups’ effects of hemodynamic variables. All tests were two-sided. A \(P < 0.05\) was considered statistically significant.

Results

All patients completed the study protocol. Thus data from all of the 50 women were analyzed in an intention-to-treat analysis [Figure 1]. There was no significant difference between the two groups regarding age, weight, ASA class, and duration of anesthesia and surgery [Table 1].

Relative to the VAS score reading 30 minutes after the end of surgery, VAS score decreased significantly in the two groups up to 48 postoperative hours [Table 2]. The VAS score was significantly lower in TDF Group than PVB Group from 30 min postoperatively up to 24 h. The time to the first request of additional analgesia was significantly longer in TDF Group \((P < 0.001)\). The total dose of morphine consumption in 48 h was significantly lower in TDF Group \((P = 0.039)\) [Table 3].

There were statistically significant changes in blood pressure and heart rate throughout the 48 postoperative hours in the two groups [Figures 2-4]. However, all changes were within the clinically accepted range. Few cases had a sedation score 2 up to the first postoperative hour; afterward, sedation score was limited to score 1 in the two groups with no significant difference. Postoperative adverse effects were limited to nausea affecting 5 patients of PVB group and 4 of TDF group \((P = 0.713)\).

Discussion

The results of this study demonstrate that TFPs in a dose of 25 \(\mu g/h\) applied 3 h before induction of anesthesia can safely...
augment the postoperative analgesic effect of PVB for 48 h after breast cancer surgery. Over the 48 h, the addition of TDF delayed demanding and reduced consumption of additional analgesia (by about 34%) with minimal sedation and limited adverse events.

In the current study, we adopted the concept of multimodal analgesia to get the effectiveness of fentanyl as an opioid agent in a small dose (25 μg/h) in addition to the thoracic PVB with single injection bupivacaine 0.25%. This combination was intended to prolong the duration of postoperative analgesia with the fentanyl patches beyond the immediate period of 6 h that are covered effectively with PVB. This combination proved effective to maximize efficacy with minimal side effects and reduced morphine consumption.

The transdermal delivery system is an elegant alternative to patient-controlled delivery that allows demand dosing of fentanyl at a predetermined interval. Systems are available to provide delivery rates ranging from 12.5 to 100 μg/h.[15] We have chosen the delivery of 25 μg/h as an adjuvant to PVB and not the only analgesic. Application 3 h before surgery allowed effectiveness during the early hours postoperatively.

Earlier studies used TFPs to control chronic pain rather than postoperative pain. This was owing to the slow onset and
unpredictable absorption, especially during hypothermia. However, more recently, fentanyl patches were used effectively to provide dose-dependent analgesia after lower abdominal surgery, major shoulder surgery, hemirolidectomy, major urological operations, abdominal surgery, total hip arthroplasty, and total knee arthroplasty.

During thoracoabdominal surgery for esophageal cancer, Osipova et al. used fentanyl patches 12 h before anesthesia with a release rate of 50 μg/h. This procedure prevented early postanesthetic acute opioid tolerance, hyperalgesia, and destabilization state. The authors found this the basis for continuous multimodal postoperative analgesia in combination with nonopioid components.

In the current study, minimal side effects were observed in the form of few patients suffering nausea and only 2 cases of vomiting. We did not observe any case of respiratory depression or deep sedation. These minimal adverse reactions are most probably due to the small release rate of fentanyl used in this study as these effects are dose-dependent, similar to other narcotic administration. Bülow et al. found the administration of 100 μg/h would be too potent, because of the potential for life-threatening respiratory depression.

Conclusion

We can conclude that TFPs releasing 25 μg/h are a safe and effective adjuvant to PVB after breast cancer surgery. It provides adequate analgesia with reduction of opioid consumption and minimal adverse effects.

Financial support and sponsorship
Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: Results of the national population-based cancer registry program. J Cancer Epidemiol 2014;2014:437971.
3. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: Results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003;97:534-40.
4. Joshi GP, Ogunnaike BO. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. Anesthesiol Clin North America 2005;23:21-36.
5. Bolin ED, Harvey NR, Wilson SH. Regional Anesthesia for breast surgery: Techniques and benefits. Curr Anesthesiol Rep 2015;5:217-24.
6. Simpson J, Ariyarathean A, Dunn J, Ford P. Breast surgery using thoracic paravertebral blockade and sedation alone. Anesthesiol Res Pract 2014;2014:127467.
7. Fahy AS, Jakub JW, Dwy BM, Eldin HS, Harmsen S, Svigum H, et al. Paravertebral blocks in patients undergoing mastectomy with or without immediate reconstruction provides improved pain control and decreased postoperative nausea and vomiting. Ann Surg Oncol 2014;21:3284-9.
8. Thompson JP, Bower S, Liddle AM, Rowbotham DJ. Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth 1998;81:152-6.
9. Duthie DJ, Rowbotham DJ, Wylde R, Henderson PD, Nimmo WS. Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. Br J Anaesth 1988;60:614-8.
10. Kornick CA, Santiago-Palma J, Khajinaova N, Primavera LH, Payne R, Manfredi PL. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer 2001;92:3056-61.
11. Kornick CA, Santiago-Palma J, Moryl N, Payne R, Obbens EA. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003;26:951-73.
12. Katz J. Atlas of Regional Anesthesia. 2nd ed. Norwalk: Appleton and Lange; 1994.
13. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, et al. Validity and reliability of the Observer’s Assessment of Alertness/Sedation Scale: Study with intravenous midazolam. J Clin Psychopharmacol 1990;10:244-51.
14. Sathitkarnmanee T, Tribuddharat S, Noiphitak K, Theerapongpakdee S, Pongjanyakul S, Huntula Y, et al. Transdermal fentanyl patch for postoperative analgesia in total knee arthroplasty: A randomized double-blind controlled trial. J Pain Res 2014;7:449-54.
15. Gupta H, Babu RJ. Transdermal delivery: Product and patent update. Recent Pat Drug Deliv Formul 2013;7:184-205.
16. Caplan RA, Ready LB, Eden RV, Matsen FA, Nessly ML, Olsson GL. Transdermal fentanyl for postoperative pain management. A double-blind placebo study. JAMA 1989;261:1036-9.
17. Broome IJ, Wright BM, Bower S, Reilly CS. Postoperative analgesia with transdermal fentanyl following lower abdominal surgery. Anaesthesia 1995;50:300-3.
18. Kilbride M, Morse M, Senagore A. Transdermal fentanyl improves management of postoperative hemorrhoidectomy pain. Dis Colon Rectum 1994;37:1070-2.
19. Lehmann KA, Einolf C, Eberlein HJ, Nagel R. Transdermal fentanyl for the treatment of pain after major urological operations. A randomized double-blind comparison with placebo using intravenous...
patient-controlled analgesia. Eur J Clin Pharmacol 1991;41:17-21.

20. Lehmann LJ, DeSio JM, Radavany T, Bikhazi GB. Transdermal fentanyl in postoperative pain. Reg Anesth 1997;22:24-8.

21. Minville V, Lubrano V, Bounces V, Pianezza A, Rabinowitz A, Gris C, et al. Postoperative analgesia after total hip arthroplasty: Patient-controlled analgesia versus transdermal fentanyl patch. J Clin Anesth 2008;20:280-3.

22. Osipova NA, Petrova VV, Lastukhin AV, Kudriavtsev SB, Vashakmadze LA, Khomiakov VM. Prevention and treatment of postoperative pain syndrome in extensive thoracoabdominal oncological surgery. Anesteziol Reanimatol 2010;(3):29-33.

23. Bülow HH, Linnemann M, Berg H, Lang-Jensen T, LaCour S, Jonsson T. Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl. Acta Anaesthesiol Scand 1995;39:835-9.